TLR7 agonist RO7020531 versus placebo in healthy volunteers and patients with chronic hepatitis B virus infection: a randomised, observer-blind, placebo-controlled, phase 1 trial-Reference-Cited by-同舟云学术

TLR7 agonist RO7020531 versus placebo in healthy volunteers and patients with chronic hepatitis B virus infection: a randomised, observer-blind, placebo-controlled, phase 1 trial

Published:2023-04 Issue:4 Volume:23 Page:496-507
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Yuen Man-Fung,Balabanska Rozalina,Cottreel Emmanuelle,Chen Ethan,Duan Dan,Jiang Qiudi,Patil Avinash,Triyatni Miriam,Upmanyu Ruchi,Zhu Yonghong,Canducci Filippo,Gane Edward J

Funder

F Hoffmann-La Roche Ltd

F. Hoffmann-La Roche

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference28 articles.

1. Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis;Anderson;Clin Gastroenterol Hepatol,2021

2. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: a meta-analysis;Song;J Viral Hepat,2021

3. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability;Kim;Gut,2014

4. Therapeutic strategies for hepatitis B virus infection: towards a cure;Fanning;Nat Rev Drug Discov,2019

5. Interaction between hepatitis B virus and Toll-like receptors: current status and potential therapeutic use for chronic hepatitis B;Ma;Vaccines (Basel),2018

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel mechanistic insights – A brand new Era for anti-HBV drugs;European Journal of Medicinal Chemistry;2024-12

2. Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like receptor 7 agonist ruzotolimod;Clinical and Translational Science;2024-08

3. The lack of HBsAg secretion does neither facilitate induction of antiviral T cell responses nor Hepatitis B Virus clearance in mice;Antiviral Research;2024-06

4. Hepatitis B: Model Systems and Therapeutic Approaches;Journal of Immunology Research;2024-05-07

5. Revolutionizing medicine with toll-like receptors: A path to strengthening cellular immunity;International Journal of Biological Macromolecules;2023-12